首页 > 最新文献

Multiple Sclerosis International最新文献

英文 中文
Adipsin Is Associated with Multiple Sclerosis: A Follow-Up Study of Adipokines 脂肪素与多发性硬化症相关:一项脂肪因子的随访研究
IF 2.5 Q3 CLINICAL NEUROLOGY Pub Date : 2015-11-08 DOI: 10.1155/2015/371734
Renuka Natarajan, S. Hagman, Mari Hämälainen, T. Leppänen, P. Dastidar, E. Moilanen, I. Elovaara
Background and Objective. The role of adipokines in regulation of immune responses has been recognized, but very little is known about their impact on multiple sclerosis (MS). In this study, we analysed whether the major adipokines are differentially expressed in plasma of patients with different MS subtypes and clinically isolated syndrome (CIS) and explored their association with major disease characteristics. Methods. The levels of adiponectin, adipsin, leptin, and resistin in the plasma of 80 patients with different subtypes of MS and CIS were followed up annually over the two years. The data obtained were correlated with disease activity, EDSS and volumes of T1-weighted lesions (T1-LV), and fluid attenuation inversion recovery lesions (FLAIR-LV) on MRI. Results. In MS group, a correlation was found between the level of adipsin and EDSS score at baseline (r = 0.506, p < 0.001). In RRMS, the levels of adipsin correlated with EDSS scores (r = 0.542, p = 0.002), T1-LV (r = 0.410, p = 0.034), and FLAIR-LV (r = 0.601, p = 0.0001) at baseline and an increase in the T1-LV over the follow-up (r = 0.582, p = 0.003). Associations with other adipokines were not detected. Conclusion. Our exploratory study provides novel insights on the impact of adipokines in MS and suggests that adipsin exerts predictive potential as a biomarker of neurodegeneration.
背景和目的。脂肪因子在调节免疫应答中的作用已被认识到,但对其在多发性硬化症(MS)中的作用知之甚少。在本研究中,我们分析了不同MS亚型和临床孤立综合征(CIS)患者血浆中主要脂肪因子是否存在差异表达,并探讨其与主要疾病特征的关系。方法。每年随访80例不同亚型MS和CIS患者血浆脂联素、脂素、瘦素和抵抗素水平,为期2年。所获得的数据与疾病活动性、EDSS和t1加权病变(T1-LV)的体积以及MRI上的液体衰减反转恢复病变(FLAIR-LV)相关。结果。MS组adipsin水平与基线EDSS评分存在相关性(r = 0.506, p < 0.001)。在RRMS中,adipsin水平与基线时EDSS评分(r = 0.542, p = 0.002)、T1-LV (r = 0.410, p = 0.034)和FLAIR-LV (r = 0.601, p = 0.0001)相关,随访期间T1-LV升高(r = 0.582, p = 0.003)。未发现与其他脂肪因子的关联。结论。我们的探索性研究为脂肪因子在多发性硬化症中的影响提供了新的见解,并表明脂肪素作为神经变性的生物标志物具有预测潜力。
{"title":"Adipsin Is Associated with Multiple Sclerosis: A Follow-Up Study of Adipokines","authors":"Renuka Natarajan, S. Hagman, Mari Hämälainen, T. Leppänen, P. Dastidar, E. Moilanen, I. Elovaara","doi":"10.1155/2015/371734","DOIUrl":"https://doi.org/10.1155/2015/371734","url":null,"abstract":"Background and Objective. The role of adipokines in regulation of immune responses has been recognized, but very little is known about their impact on multiple sclerosis (MS). In this study, we analysed whether the major adipokines are differentially expressed in plasma of patients with different MS subtypes and clinically isolated syndrome (CIS) and explored their association with major disease characteristics. Methods. The levels of adiponectin, adipsin, leptin, and resistin in the plasma of 80 patients with different subtypes of MS and CIS were followed up annually over the two years. The data obtained were correlated with disease activity, EDSS and volumes of T1-weighted lesions (T1-LV), and fluid attenuation inversion recovery lesions (FLAIR-LV) on MRI. Results. In MS group, a correlation was found between the level of adipsin and EDSS score at baseline (r = 0.506, p < 0.001). In RRMS, the levels of adipsin correlated with EDSS scores (r = 0.542, p = 0.002), T1-LV (r = 0.410, p = 0.034), and FLAIR-LV (r = 0.601, p = 0.0001) at baseline and an increase in the T1-LV over the follow-up (r = 0.582, p = 0.003). Associations with other adipokines were not detected. Conclusion. Our exploratory study provides novel insights on the impact of adipokines in MS and suggests that adipsin exerts predictive potential as a biomarker of neurodegeneration.","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2015 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2015-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/371734","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"64927594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 21
Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis. 世界视神经脊髓炎的流行病学:系统回顾和荟萃分析。
IF 2.5 Q3 CLINICAL NEUROLOGY Pub Date : 2015-01-01 Epub Date: 2015-04-20 DOI: 10.1155/2015/174720
Masoud Etemadifar, Zahra Nasr, Behrang Khalili, Maryam Taherioun, Reza Vosoughi

Background. Neuromyelitis optica (Devic's disease) is a severe autoimmune inflammatory disorder of the central nervous system. Epidemiological aspects of NMO have not been systemically reviewed. In this study we systematically reviewed and assessed the quality of studies reporting the incidence and/or prevalence of NMO across the world. Methods. A comprehensive literature search using MEDLINE, EMBASE, and Web of Science for the terms "Neuromyelitis optica," "devic disease," "incidence," "prevalence," and "epidemiology" was conducted on January 31, 2015. Study quality was assessed using an assessment tool based on recognized guidelines and designed specifically for this study. Results. A total of 216 studies were initially identified, with only 9 meeting the inclusion criteria. High level of heterogeneity amongst studies precluded a firm conclusion. Incidence data were found in four studies and ranged from 0.053 per 100,000 per year in Cuba to 0.4 in Southern Denmark. Prevalence was reported in all studies and ranged from 0.51 per 100,000 in Cuba to 4.4 in Southern Denmark. Conclusion. This review reveals the gaps that still exist in the epidemiological knowledge of NMO in the world. Published studies have different qualities and methodology precluding a robust conclusion. Future researches focusing on epidemiological features of NMO in different nations and different ethnic groups are needed.

背景。视神经脊髓炎是一种严重的中枢神经系统自身免疫性炎症性疾病。NMO的流行病学方面尚未得到系统审查。在这项研究中,我们系统地回顾和评估了报告全球NMO发病率和/或患病率的研究的质量。方法。2015年1月31日,使用MEDLINE、EMBASE和Web of Science对“视神经脊髓炎”、“器械疾病”、“发病率”、“患病率”和“流行病学”进行了全面的文献检索。使用基于公认指南的评估工具对研究质量进行评估,该工具是专门为本研究设计的。结果。最初共纳入216项研究,其中只有9项符合纳入标准。研究之间的高度异质性妨碍了确定的结论。在四项研究中发现了发病率数据,从古巴每年0.053 / 10万到丹麦南部每年0.4 / 10万不等。所有研究都报告了患病率,从古巴的0.51 / 10万到丹麦南部的4.4 / 10万不等。结论。这一综述揭示了国际上对NMO的流行病学知识仍然存在的差距。已发表的研究具有不同的质量和方法,因此无法得出可靠的结论。今后还需要进一步研究不同民族、不同民族的NMO流行病学特征。
{"title":"Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis.","authors":"Masoud Etemadifar,&nbsp;Zahra Nasr,&nbsp;Behrang Khalili,&nbsp;Maryam Taherioun,&nbsp;Reza Vosoughi","doi":"10.1155/2015/174720","DOIUrl":"https://doi.org/10.1155/2015/174720","url":null,"abstract":"<p><p>Background. Neuromyelitis optica (Devic's disease) is a severe autoimmune inflammatory disorder of the central nervous system. Epidemiological aspects of NMO have not been systemically reviewed. In this study we systematically reviewed and assessed the quality of studies reporting the incidence and/or prevalence of NMO across the world. Methods. A comprehensive literature search using MEDLINE, EMBASE, and Web of Science for the terms \"Neuromyelitis optica,\" \"devic disease,\" \"incidence,\" \"prevalence,\" and \"epidemiology\" was conducted on January 31, 2015. Study quality was assessed using an assessment tool based on recognized guidelines and designed specifically for this study. Results. A total of 216 studies were initially identified, with only 9 meeting the inclusion criteria. High level of heterogeneity amongst studies precluded a firm conclusion. Incidence data were found in four studies and ranged from 0.053 per 100,000 per year in Cuba to 0.4 in Southern Denmark. Prevalence was reported in all studies and ranged from 0.51 per 100,000 in Cuba to 4.4 in Southern Denmark. Conclusion. This review reveals the gaps that still exist in the epidemiological knowledge of NMO in the world. Published studies have different qualities and methodology precluding a robust conclusion. Future researches focusing on epidemiological features of NMO in different nations and different ethnic groups are needed. </p>","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2015 ","pages":"174720"},"PeriodicalIF":2.5,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/174720","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33303413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 99
Does Self-Efficacy Affect Cognitive Performance in Persons with Clinically Isolated Syndrome and Early Relapsing Remitting Multiple Sclerosis? 自我效能感是否影响临床孤立综合征和早期复发缓解型多发性硬化症患者的认知表现?
IF 2.5 Q3 CLINICAL NEUROLOGY Pub Date : 2015-01-01 Epub Date: 2015-04-29 DOI: 10.1155/2015/960282
Peter Joseph Jongen, Keith Wesnes, Björn van Geel, Paul Pop, Hans Schrijver, Leo H Visser, H Jacobus Gilhuis, Ludovicus G Sinnige, Augustina M Brands

In persons with multiple sclerosis (MS) a lowered self-efficacy negatively affects physical activities. Against this background we studied the relationship between self-efficacy and cognitive performance in the early stages of MS. Thirty-three patients with Clinically Isolated Syndrome (CIS) and early Relapsing Remitting MS (eRRMS) were assessed for self-efficacy (MSSES-18), cognition (CDR System), fatigue (MFIS-5), depressive symptoms (BDI), disease impact (MSIS-29), and disability (EDSS). Correlative analyses were performed between self-efficacy and cognitive scores, and stepwise regression analyses identified predictors of cognition and self-efficacy. Good correlations existed between total self-efficacy and Power of Attention (r= 0.65; P< 0.001), Reaction Time Variability (r= 0.57; P< 0.001), and Speed of Memory (r= 0.53; P< 0.01), and between control self-efficacy and Reaction Time Variability (r= 0.55; P< 0.01). Total self-efficacy predicted 40% of Power of Attention, 34% of Reaction Time Variability, and 40% of Speed of Memory variabilities. Disease impact predicted 65% of total self-efficacy and 58% of control self-efficacy variabilities. The findings may suggest that in persons with CIS and eRRMS self-efficacy may positively affect cognitive performance and that prevention of disease activity may preserve self-efficacy.

在多发性硬化症(MS)患者中,自我效能降低会对身体活动产生负面影响。在此背景下,我们研究了33例临床孤立综合征(CIS)和早期复发缓解型MS (eRRMS)患者的自我效能(msss -18)、认知(CDR系统)、疲劳(mss -5)、抑郁症状(BDI)、疾病影响(MSIS-29)和残疾(EDSS)。自我效能感与认知得分之间进行相关分析,逐步回归分析认知与自我效能感的预测因子。总自我效能感与注意力之间存在良好的相关关系(r= 0.65;P< 0.001),反应时间变异性(r= 0.57;P< 0.001),内存速度(r= 0.53;P< 0.01),对照自我效能感与反应时间变异性之间差异有统计学意义(r= 0.55;P < 0.01)。总自我效能能预测40%的注意力、34%的反应时间变异性和40%的记忆速度变异性。疾病影响预测65%的总自我效能和58%的控制自我效能变量。研究结果可能表明,在CIS和eRRMS患者中,自我效能感可能积极影响认知表现,预防疾病活动可能保持自我效能感。
{"title":"Does Self-Efficacy Affect Cognitive Performance in Persons with Clinically Isolated Syndrome and Early Relapsing Remitting Multiple Sclerosis?","authors":"Peter Joseph Jongen,&nbsp;Keith Wesnes,&nbsp;Björn van Geel,&nbsp;Paul Pop,&nbsp;Hans Schrijver,&nbsp;Leo H Visser,&nbsp;H Jacobus Gilhuis,&nbsp;Ludovicus G Sinnige,&nbsp;Augustina M Brands","doi":"10.1155/2015/960282","DOIUrl":"https://doi.org/10.1155/2015/960282","url":null,"abstract":"<p><p>In persons with multiple sclerosis (MS) a lowered self-efficacy negatively affects physical activities. Against this background we studied the relationship between self-efficacy and cognitive performance in the early stages of MS. Thirty-three patients with Clinically Isolated Syndrome (CIS) and early Relapsing Remitting MS (eRRMS) were assessed for self-efficacy (MSSES-18), cognition (CDR System), fatigue (MFIS-5), depressive symptoms (BDI), disease impact (MSIS-29), and disability (EDSS). Correlative analyses were performed between self-efficacy and cognitive scores, and stepwise regression analyses identified predictors of cognition and self-efficacy. Good correlations existed between total self-efficacy and Power of Attention (r= 0.65; P< 0.001), Reaction Time Variability (r= 0.57; P< 0.001), and Speed of Memory (r= 0.53; P< 0.01), and between control self-efficacy and Reaction Time Variability (r= 0.55; P< 0.01). Total self-efficacy predicted 40% of Power of Attention, 34% of Reaction Time Variability, and 40% of Speed of Memory variabilities. Disease impact predicted 65% of total self-efficacy and 58% of control self-efficacy variabilities. The findings may suggest that in persons with CIS and eRRMS self-efficacy may positively affect cognitive performance and that prevention of disease activity may preserve self-efficacy. </p>","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2015 ","pages":"960282"},"PeriodicalIF":2.5,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/960282","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33379066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
Development of Activity-Related Muscle Fatigue during Robot-Mediated Upper Limb Rehabilitation Training in Persons with Multiple Sclerosis: A Pilot Trial. 多发性硬化症患者在机器人介导的上肢康复训练中活动相关肌肉疲劳的发展:一项试点试验。
IF 2.5 Q3 CLINICAL NEUROLOGY Pub Date : 2015-01-01 Epub Date: 2015-05-24 DOI: 10.1155/2015/650431
Johanna Renny Octavia, Peter Feys, Karin Coninx

Robot-assisted rehabilitation facilitates high-intensity training of the impaired upper limb in neurological rehabilitation. It has been clinically observed that persons with Multiple Sclerosis (MS) have difficulties in sustaining the training intensity during a session due to the development of activity-related muscle fatigue. An experimental observational pilot study was conducted to examine whether or not the muscle fatigue develops in MS patients during one session of robot-assisted training within a virtual learning environment. Six MS patients with upper limb impairment (motricity index ranging from 50 to 91/100) and six healthy persons completed five training bouts of three minutes each performing lifting tasks, while EMG signals of anterior deltoid and lower trapezius muscles were measured and their subjective perceptions on muscle fatigue were registered. Decreased performance and higher subjective fatigue perception were present in the MS group. Increased mean EMG amplitudes and subjective perception levels on muscle fatigue were observed in both groups. Muscle fatigue development during 15' training has been demonstrated in the arm of MS patients, which influences the sustainability of training intensity in MS patients. To optimize the training performance, adaptivity based on the detection of MS patient's muscle fatigue could be provided by means of training program adjustment.

机器人辅助康复为神经康复中上肢损伤的高强度训练提供了便利。临床观察发现,多发性硬化症(MS)患者由于活动相关肌肉疲劳的发展,在一次训练中难以维持训练强度。进行了一项实验性观察性先导研究,以检查在虚拟学习环境中进行机器人辅助训练的MS患者是否会出现肌肉疲劳。6例上肢损伤的MS患者(运动指数50 ~ 91/100)和6名健康人完成5组每次3分钟的举重训练,测量前三角肌和下斜方肌肌电图信号,记录其对肌肉疲劳的主观感受。MS组表现下降,主观疲劳感升高。在两组中均观察到肌电图平均振幅和主观感觉水平的增加。MS患者手臂在15'训练中出现肌肉疲劳发展,影响MS患者训练强度的可持续性。为了优化训练效果,可以通过调整训练方案,在检测MS患者肌肉疲劳的基础上提供适应性。
{"title":"Development of Activity-Related Muscle Fatigue during Robot-Mediated Upper Limb Rehabilitation Training in Persons with Multiple Sclerosis: A Pilot Trial.","authors":"Johanna Renny Octavia,&nbsp;Peter Feys,&nbsp;Karin Coninx","doi":"10.1155/2015/650431","DOIUrl":"https://doi.org/10.1155/2015/650431","url":null,"abstract":"<p><p>Robot-assisted rehabilitation facilitates high-intensity training of the impaired upper limb in neurological rehabilitation. It has been clinically observed that persons with Multiple Sclerosis (MS) have difficulties in sustaining the training intensity during a session due to the development of activity-related muscle fatigue. An experimental observational pilot study was conducted to examine whether or not the muscle fatigue develops in MS patients during one session of robot-assisted training within a virtual learning environment. Six MS patients with upper limb impairment (motricity index ranging from 50 to 91/100) and six healthy persons completed five training bouts of three minutes each performing lifting tasks, while EMG signals of anterior deltoid and lower trapezius muscles were measured and their subjective perceptions on muscle fatigue were registered. Decreased performance and higher subjective fatigue perception were present in the MS group. Increased mean EMG amplitudes and subjective perception levels on muscle fatigue were observed in both groups. Muscle fatigue development during 15' training has been demonstrated in the arm of MS patients, which influences the sustainability of training intensity in MS patients. To optimize the training performance, adaptivity based on the detection of MS patient's muscle fatigue could be provided by means of training program adjustment. </p>","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2015 ","pages":"650431"},"PeriodicalIF":2.5,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/650431","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33402958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
Antiepileptic and Antidepressive Polypharmacy in Patients with Multiple Sclerosis. 多发性硬化症患者的抗癫痫和抗抑郁综合用药。
IF 2.5 Q3 CLINICAL NEUROLOGY Pub Date : 2015-01-01 Epub Date: 2015-06-29 DOI: 10.1155/2015/317859
Georg Anton Giæver Beiske, Trygve Holmøy, Antonie Giæver Beiske, Svein I Johannessen, Cecilie Johannessen Landmark

Objective. Patients with multiple sclerosis (MS) are often suffering from neuropathic pain. Antiepileptic drugs (AEDs) and tricyclic antidepressants (TCAs) are commonly used and are susceptible to be involved in drug interactions. The aim of this retrospective study was to investigate the prevalence of use of antiepileptic and antidepressive drugs in MS patients and to discuss the theoretical potential for interactions. Methods. Review of the medical records from all patients treated at a dedicated MS rehabilitation centre in Norway between 2009 and 2012. Results. In total 1090 patients attended a rehabilitation stay during the study period. Of these, 342 (31%; 249 females) with mean age of 53 (±10) years and EDSS 4.8 (±1.7) used at least one AED (gabapentin 12.7%, pregabalin 7.7%, clonazepam 7.8%, and carbamazepine 2.6%) or amitriptyline (9.7%). Polypharmacy was widespread (mean 5.4 drugs) with 60% using additional CNS-active drugs with a propensity to be involved in interactions. Age, gender, and EDSS scores did not differ significantly between those using and not using AED/amitriptyline. Conclusion. One-third of MS patients attending a rehabilitation stay receive AED/amitriptyline treatment. The high prevalence of polypharmacy and use of CNS-active drugs calls for awareness of especially pharmacodynamic interactions and possible excessive adverse effects.

目标。多发性硬化症(MS)患者经常遭受神经性疼痛。抗癫痫药(AEDs)和三环抗抑郁药(TCAs)是常用的药物,容易参与药物相互作用。本回顾性研究的目的是调查多发性硬化症患者使用抗癫痫和抗抑郁药物的患病率,并讨论相互作用的理论潜力。方法。回顾2009年至2012年期间在挪威一家专门的多发性硬化症康复中心接受治疗的所有患者的医疗记录。结果。在研究期间,总共有1090名患者接受了康复治疗。其中,342人(31%;249名女性),平均年龄53(±10)岁,EDSS 4.8(±1.7)岁,使用至少一种AED(加巴喷丁12.7%,普瑞巴林7.7%,氯硝西泮7.8%,卡马西平2.6%)或阿米替林9.7%。多药的情况很普遍(平均5.4种药物),60%的患者使用额外的中枢神经系统活性药物,这些药物倾向于参与相互作用。使用和不使用AED/阿米替林的患者的年龄、性别和EDSS评分没有显著差异。结论。三分之一接受康复治疗的MS患者接受AED/阿米替林治疗。多药联用和中枢神经系统活性药物的高流行要求认识到特别是药效学相互作用和可能的过度不良反应。
{"title":"Antiepileptic and Antidepressive Polypharmacy in Patients with Multiple Sclerosis.","authors":"Georg Anton Giæver Beiske,&nbsp;Trygve Holmøy,&nbsp;Antonie Giæver Beiske,&nbsp;Svein I Johannessen,&nbsp;Cecilie Johannessen Landmark","doi":"10.1155/2015/317859","DOIUrl":"https://doi.org/10.1155/2015/317859","url":null,"abstract":"<p><p>Objective. Patients with multiple sclerosis (MS) are often suffering from neuropathic pain. Antiepileptic drugs (AEDs) and tricyclic antidepressants (TCAs) are commonly used and are susceptible to be involved in drug interactions. The aim of this retrospective study was to investigate the prevalence of use of antiepileptic and antidepressive drugs in MS patients and to discuss the theoretical potential for interactions. Methods. Review of the medical records from all patients treated at a dedicated MS rehabilitation centre in Norway between 2009 and 2012. Results. In total 1090 patients attended a rehabilitation stay during the study period. Of these, 342 (31%; 249 females) with mean age of 53 (±10) years and EDSS 4.8 (±1.7) used at least one AED (gabapentin 12.7%, pregabalin 7.7%, clonazepam 7.8%, and carbamazepine 2.6%) or amitriptyline (9.7%). Polypharmacy was widespread (mean 5.4 drugs) with 60% using additional CNS-active drugs with a propensity to be involved in interactions. Age, gender, and EDSS scores did not differ significantly between those using and not using AED/amitriptyline. Conclusion. One-third of MS patients attending a rehabilitation stay receive AED/amitriptyline treatment. The high prevalence of polypharmacy and use of CNS-active drugs calls for awareness of especially pharmacodynamic interactions and possible excessive adverse effects. </p>","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2015 ","pages":"317859"},"PeriodicalIF":2.5,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/317859","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33878459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 22
Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study. 疾病改善药物减少复发缓解型多发性硬化症皮质病变积累和萎缩进展:一项为期48个月的扩展研究的结果
IF 2.5 Q3 CLINICAL NEUROLOGY Pub Date : 2015-01-01 Epub Date: 2015-02-23 DOI: 10.1155/2015/369348
Francesca Rinaldi, Paola Perini, Matteo Atzori, Alice Favaretto, Dario Seppi, Paolo Gallo
Cortical lesions (CLs) and atrophy are pivotal in multiple sclerosis (MS) pathology. This study determined the effect of disease modifying drugs (DMDs) on CL development and cortical atrophy progression in patients with relapsing-remitting MS (RRMS) over 48 months. Patients (n = 165) were randomized to sc IFN β-1a 44 μg, im IFN β-1a 30 μg, or glatiramer acetate 20 mg. The reference population comprised 50 DMD-untreated patients with RRMS. After 24 months, 43 of the untreated patients switched to DMDs. The four groups of patients were followed up for an additional 24 months. At 48 months the mean standard deviation number of new CLs was significantly lower in patients treated with sc IFN β-1a (1.4 ± 1.0, range 0–5) compared with im IFN β-1a (2.3 ± 1.3, range 0–6, P = 0.004) and glatiramer acetate (2.2 ± 1.5, range 0–7, P = 0.03). Significant reductions in CL accumulation and new white matter and gadolinium-enhancing lesions were also observed in the 43 patients who switched to DMDs after 24 months, compared with the 24 months of no treatment. Concluding, this study confirms that DMDs significantly reduce CL development and cortical atrophy progression compared with no treatment.
皮质病变(CLs)和萎缩是关键的多发性硬化症(MS)病理。这项研究确定了疾病调节药物(dmd)对复发-缓解型MS (RRMS)患者超过48个月的CL发展和皮质萎缩进展的影响。165例患者随机分为3组,1组IFN β-1a 44 μg, 2组IFN β-1a 30 μg, 3组醋酸格拉替雷默20 mg。参考人群包括50名未经dmd治疗的RRMS患者。24个月后,43名未经治疗的患者改用dmd。四组患者随访24个月。48个月时,sc IFN β-1a组新发CLs的平均标准差数(1.4±1.0,范围0-5)明显低于im IFN β-1a组(2.3±1.3,范围0-6,P = 0.004)和醋酸格拉替雷明组(2.2±1.5,范围0-7,P = 0.03)。与24个月未治疗的43例患者相比,在24个月后改用dmd的患者中,还观察到CL积累、新白质和钆增强病变的显著减少。总之,本研究证实,与未治疗相比,dmd可显著减少CL的发生和皮质萎缩的进展。
{"title":"Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study.","authors":"Francesca Rinaldi,&nbsp;Paola Perini,&nbsp;Matteo Atzori,&nbsp;Alice Favaretto,&nbsp;Dario Seppi,&nbsp;Paolo Gallo","doi":"10.1155/2015/369348","DOIUrl":"https://doi.org/10.1155/2015/369348","url":null,"abstract":"Cortical lesions (CLs) and atrophy are pivotal in multiple sclerosis (MS) pathology. This study determined the effect of disease modifying drugs (DMDs) on CL development and cortical atrophy progression in patients with relapsing-remitting MS (RRMS) over 48 months. Patients (n = 165) were randomized to sc IFN β-1a 44 μg, im IFN β-1a 30 μg, or glatiramer acetate 20 mg. The reference population comprised 50 DMD-untreated patients with RRMS. After 24 months, 43 of the untreated patients switched to DMDs. The four groups of patients were followed up for an additional 24 months. At 48 months the mean standard deviation number of new CLs was significantly lower in patients treated with sc IFN β-1a (1.4 ± 1.0, range 0–5) compared with im IFN β-1a (2.3 ± 1.3, range 0–6, P = 0.004) and glatiramer acetate (2.2 ± 1.5, range 0–7, P = 0.03). Significant reductions in CL accumulation and new white matter and gadolinium-enhancing lesions were also observed in the 43 patients who switched to DMDs after 24 months, compared with the 24 months of no treatment. Concluding, this study confirms that DMDs significantly reduce CL development and cortical atrophy progression compared with no treatment.","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2015 ","pages":"369348"},"PeriodicalIF":2.5,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/369348","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33156374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
The Lived Experience of Multiple Sclerosis Relapse: How Adults with Multiple Sclerosis Processed Their Relapse Experience and Evaluated Their Need for Postrelapse Care. 多发性硬化症复发的生活经历:多发性硬化症成人如何处理他们的复发经历并评估他们对复发后护理的需求。
IF 2.5 Q3 CLINICAL NEUROLOGY Pub Date : 2015-01-01 Epub Date: 2015-05-13 DOI: 10.1155/2015/351416
Miho Asano, Karli Hawken, Merrill Turpin, Abby Eitzen, Marcia Finlayson

Background. Multiple sclerosis (MS) relapses can take a toll on individuals' health and quality of life. Given such consequences of relapses, postrelapse care beyond pharmacological approaches may play an important role in recovery. Nevertheless, how individuals with MS process their relapse experience and manage the consequences is still uncertain. Purpose. We conducted a qualitative study to understand relapse experiences and postrelapse care need from perspectives of adults with MS and identify relapse management patterns. Methods. We interviewed 17 adults with MS. Results. By examining combinations of three categories related to relapse experience, we identified four relapse management patterns: (i) Active Relapse Manager, (ii) Early-Stage Proactive Relapse Monitor, (iii) Adapted Passive Relapse Manager, and (iv) Passive Relapse Monitor. The relapse management patterns appear to associate strongly with the appraisal of the experience. Conclusions. The results of this study suggest the importance of understanding each patient beyond their functional limitations and the potential need for multidisciplinary postrelapse care which goes past restoring functional limitations at the acute phase. Future research to further understand the relapse management process at all stages of the healthcare continuum is a crucial step toward developing strategies to advance the current postrelapse care and to facilitate optimal recovery.

背景。多发性硬化症(MS)的复发会对个人的健康和生活质量造成损害。考虑到这些复发的后果,药物治疗之外的复发后护理可能在康复中发挥重要作用。然而,多发性硬化症患者如何处理他们的复发经历和处理后果仍然不确定。目的。我们进行了一项定性研究,从成人多发性硬化症患者的角度了解复发经历和复发后护理需求,并确定复发管理模式。方法。我们采访了17名患有多发性硬化症的成年人。通过检查与复发经验相关的三类组合,我们确定了四种复发管理模式:(i)主动复发管理,(ii)早期主动复发监测,(iii)适应性被动复发管理,(iv)被动复发监测。复发管理模式似乎与对经历的评价密切相关。结论。这项研究的结果表明,了解每个病人的重要性,超越他们的功能限制和潜在的需要多学科的复发后护理,超过恢复功能限制在急性期。未来的研究将进一步了解在医疗连续体的各个阶段的复发管理过程,这是制定策略以推进当前复发后护理和促进最佳恢复的关键一步。
{"title":"The Lived Experience of Multiple Sclerosis Relapse: How Adults with Multiple Sclerosis Processed Their Relapse Experience and Evaluated Their Need for Postrelapse Care.","authors":"Miho Asano,&nbsp;Karli Hawken,&nbsp;Merrill Turpin,&nbsp;Abby Eitzen,&nbsp;Marcia Finlayson","doi":"10.1155/2015/351416","DOIUrl":"https://doi.org/10.1155/2015/351416","url":null,"abstract":"<p><p>Background. Multiple sclerosis (MS) relapses can take a toll on individuals' health and quality of life. Given such consequences of relapses, postrelapse care beyond pharmacological approaches may play an important role in recovery. Nevertheless, how individuals with MS process their relapse experience and manage the consequences is still uncertain. Purpose. We conducted a qualitative study to understand relapse experiences and postrelapse care need from perspectives of adults with MS and identify relapse management patterns. Methods. We interviewed 17 adults with MS. Results. By examining combinations of three categories related to relapse experience, we identified four relapse management patterns: (i) Active Relapse Manager, (ii) Early-Stage Proactive Relapse Monitor, (iii) Adapted Passive Relapse Manager, and (iv) Passive Relapse Monitor. The relapse management patterns appear to associate strongly with the appraisal of the experience. Conclusions. The results of this study suggest the importance of understanding each patient beyond their functional limitations and the potential need for multidisciplinary postrelapse care which goes past restoring functional limitations at the acute phase. Future research to further understand the relapse management process at all stages of the healthcare continuum is a crucial step toward developing strategies to advance the current postrelapse care and to facilitate optimal recovery. </p>","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2015 ","pages":"351416"},"PeriodicalIF":2.5,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/351416","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33263389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Prevalence of Depression and Anxiety among Patients with Multiple Sclerosis Attending the MS Clinic at Sheikh Khalifa Medical City, UAE: Cross-Sectional Study. 阿联酋谢赫哈利法医疗城多发性硬化症门诊患者抑郁和焦虑的患病率:横断面研究
IF 2.5 Q3 CLINICAL NEUROLOGY Pub Date : 2015-01-01 Epub Date: 2015-07-09 DOI: 10.1155/2015/487159
Taoufik Alsaadi, Khadija El Hammasi, Tarek M Shahrour, Mustafa Shakra, Lamya Turkawi, Abdulla Mudhafar, Lina Diab, Mufeed Raoof

Depression and anxiety are reported to be prevalent in patients with MS, with prevalence rates ranging from 20% to 50%. Unfortunately, the rates, patterns, and risk factors are not well studied in our Middle East region, and, to our knowledge, not at all in UAE. Using standardized screening tools, we observed that 17% and 20% of 80 patients seen in MS clinic had scores consistent with major depression and anxiety disorders, respectively, at a rate that was not statistically different when compared to age and sex matched controls. None of the studied variables including duration of the disease, EDSS scores, age, gender, and the level of education had any significant correlation with the rates of both disorders. Almost two-thirds of the patients with scores consistent with major depression and anxiety were not on antidepressant and antianxiety medications.

据报道,多发性硬化症患者普遍存在抑郁和焦虑,患病率从20%到50%不等。不幸的是,发病率、模式和风险因素在我们中东地区没有得到很好的研究,据我们所知,在阿联酋根本没有。使用标准化筛查工具,我们观察到在MS诊所就诊的80名患者中,分别有17%和20%的患者得分与重度抑郁症和焦虑症一致,与年龄和性别匹配的对照组相比,这一比例没有统计学差异。包括疾病持续时间、EDSS评分、年龄、性别和教育水平在内的研究变量与两种疾病的发生率均无显著相关性。几乎三分之二的得分与严重抑郁和焦虑相符的患者没有服用抗抑郁药和抗焦虑药物。
{"title":"Prevalence of Depression and Anxiety among Patients with Multiple Sclerosis Attending the MS Clinic at Sheikh Khalifa Medical City, UAE: Cross-Sectional Study.","authors":"Taoufik Alsaadi,&nbsp;Khadija El Hammasi,&nbsp;Tarek M Shahrour,&nbsp;Mustafa Shakra,&nbsp;Lamya Turkawi,&nbsp;Abdulla Mudhafar,&nbsp;Lina Diab,&nbsp;Mufeed Raoof","doi":"10.1155/2015/487159","DOIUrl":"https://doi.org/10.1155/2015/487159","url":null,"abstract":"<p><p>Depression and anxiety are reported to be prevalent in patients with MS, with prevalence rates ranging from 20% to 50%. Unfortunately, the rates, patterns, and risk factors are not well studied in our Middle East region, and, to our knowledge, not at all in UAE. Using standardized screening tools, we observed that 17% and 20% of 80 patients seen in MS clinic had scores consistent with major depression and anxiety disorders, respectively, at a rate that was not statistically different when compared to age and sex matched controls. None of the studied variables including duration of the disease, EDSS scores, age, gender, and the level of education had any significant correlation with the rates of both disorders. Almost two-thirds of the patients with scores consistent with major depression and anxiety were not on antidepressant and antianxiety medications. </p>","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2015 ","pages":"487159"},"PeriodicalIF":2.5,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/487159","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34064866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 31
Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments. 鞘内IgG合成:未来多发性硬化症治疗的一个耐药和有价值的靶点。
IF 2.5 Q3 CLINICAL NEUROLOGY Pub Date : 2015-01-01 Epub Date: 2015-01-08 DOI: 10.1155/2015/296184
Mickael Bonnan

Intrathecal IgG synthesis is a key biological feature of multiple sclerosis (MS). When acquired early, it persists over time. A growing body of evidence suggests that intrathecal Ig-secreting cells may be pathogenic either by a direct action of toxic IgG or by locally secreting bystander toxic products. Intrathecal IgG synthesis depends on the presence of CNS lymphoid organs, which are strongly linked at anatomical level to cortical subpial lesions and at clinical level to the impairment slope in progressive MS. As a consequence, targeting CNS lymphoid lesions could be a valuable new target in MS, especially during the progressive phase. As intrathecal IgGs are end-products of these lymphoid lesions, intrathecal IgG synthesis may be considered as a specific marker of the persistence of these inflammatory lesions. Here we review the effect upon intrathecal IgG synthesis of all drugs ever used in MS. Except for steroids, all these therapeutic strategies, including rituximab, failed to decrease intrathecal IgG synthesis, with the exception of a questionable incomplete action of natalizumab. Thus, IgG synthesis is a robust marker of persistent intrathecal inflammation and its complete normalization should be one of the goals in future therapeutic strategies.

鞘内IgG合成是多发性硬化症(MS)的一个关键生物学特征。如果早期获得,它会持续一段时间。越来越多的证据表明,鞘内分泌IgG的细胞可能是由有毒IgG的直接作用或局部分泌的旁观者有毒产物致病的。鞘内IgG的合成依赖于中枢神经系统淋巴器官的存在,而中枢神经系统淋巴器官在解剖学水平上与皮质基底下病变密切相关,在临床水平上与进展性多发性硬化症的损伤斜率密切相关。因此,靶向中枢神经系统淋巴病变可能是多发性硬化症治疗的一个有价值的新靶点,尤其是在进展期。由于鞘内IgG是这些淋巴样病变的最终产物,因此鞘内IgG的合成可能被认为是这些炎性病变持续存在的特异性标志。在这里,我们回顾了所有用于多发性硬化症的药物对鞘内IgG合成的影响,除了类固醇,所有这些治疗策略,包括利妥昔单抗,都未能减少鞘内IgG合成,除了那他单抗的不完全作用。因此,IgG合成是持续鞘内炎症的一个强有力的标志,其完全正常化应该是未来治疗策略的目标之一。
{"title":"Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments.","authors":"Mickael Bonnan","doi":"10.1155/2015/296184","DOIUrl":"https://doi.org/10.1155/2015/296184","url":null,"abstract":"<p><p>Intrathecal IgG synthesis is a key biological feature of multiple sclerosis (MS). When acquired early, it persists over time. A growing body of evidence suggests that intrathecal Ig-secreting cells may be pathogenic either by a direct action of toxic IgG or by locally secreting bystander toxic products. Intrathecal IgG synthesis depends on the presence of CNS lymphoid organs, which are strongly linked at anatomical level to cortical subpial lesions and at clinical level to the impairment slope in progressive MS. As a consequence, targeting CNS lymphoid lesions could be a valuable new target in MS, especially during the progressive phase. As intrathecal IgGs are end-products of these lymphoid lesions, intrathecal IgG synthesis may be considered as a specific marker of the persistence of these inflammatory lesions. Here we review the effect upon intrathecal IgG synthesis of all drugs ever used in MS. Except for steroids, all these therapeutic strategies, including rituximab, failed to decrease intrathecal IgG synthesis, with the exception of a questionable incomplete action of natalizumab. Thus, IgG synthesis is a robust marker of persistent intrathecal inflammation and its complete normalization should be one of the goals in future therapeutic strategies. </p>","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2015 ","pages":"296184"},"PeriodicalIF":2.5,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/296184","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33030113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 43
Applying an Open-Source Segmentation Algorithm to Different OCT Devices in Multiple Sclerosis Patients and Healthy Controls: Implications for Clinical Trials. 将开源分割算法应用于多发性硬化症患者和健康对照者的不同 OCT 设备:临床试验的意义
IF 2.2 Q3 CLINICAL NEUROLOGY Pub Date : 2015-01-01 Epub Date: 2015-05-18 DOI: 10.1155/2015/136295
Pavan Bhargava, Andrew Lang, Omar Al-Louzi, Aaron Carass, Jerry Prince, Peter A Calabresi, Shiv Saidha

Background. The lack of segmentation algorithms operative across optical coherence tomography (OCT) platforms hinders utility of retinal layer measures in MS trials. Objective. To determine cross-sectional and longitudinal agreement of retinal layer thicknesses derived from an open-source, fully-automated, segmentation algorithm, applied to two spectral-domain OCT devices. Methods. Cirrus HD-OCT and Spectralis OCT macular scans from 68 MS patients and 22 healthy controls were segmented. A longitudinal cohort comprising 51 subjects (mean follow-up: 1.4 ± 0.9 years) was also examined. Bland-Altman analyses and interscanner agreement indices were utilized to assess agreement between scanners. Results. Low mean differences (-2.16 to 0.26 μm) and narrow limits of agreement (LOA) were noted for ganglion cell and inner and outer nuclear layer thicknesses cross-sectionally. Longitudinally we found low mean differences (-0.195 to 0.21 μm) for changes in all layers, with wider LOA. Comparisons of rate of change in layer thicknesses over time revealed consistent results between the platforms. Conclusions. Retinal thickness measures for the majority of the retinal layers agree well cross-sectionally and longitudinally between the two scanners at the cohort level, with greater variability at the individual level. This open-source segmentation algorithm enables combining data from different OCT platforms, broadening utilization of OCT as an outcome measure in MS trials.

背景。光学相干断层扫描(OCT)平台缺乏可操作的分割算法,这阻碍了 MS 试验中视网膜层测量的实用性。目的确定应用于两种光谱域 OCT 设备的开源全自动分割算法得出的视网膜层厚度的横截面和纵向一致性。方法。对 68 名多发性硬化症患者和 22 名健康对照者的 Cirrus HD-OCT 和 Spectralis OCT 黄斑扫描图像进行分割。此外,还检查了由 51 名受试者组成的纵向队列(平均随访时间:1.4 ± 0.9 年)。利用Bland-Altman分析和扫描仪间一致性指数来评估扫描仪之间的一致性。结果显示神经节细胞、核内层和核外层横截面厚度的平均差异较小(-2.16 至 0.26 μm),一致性极限(LOA)较窄。从纵向看,我们发现各层厚度变化的平均差异较小(-0.195 至 0.21 μm),LOA 较宽。对各层厚度随时间变化的速率进行比较后发现,各平台之间的结果是一致的。结论。在群体水平上,两台扫描仪对大多数视网膜层的横截面和纵向厚度测量结果一致,但在个体水平上差异较大。这种开源的分割算法能将不同 OCT 平台的数据结合起来,扩大了 OCT 作为 MS 试验结果测量方法的应用范围。
{"title":"Applying an Open-Source Segmentation Algorithm to Different OCT Devices in Multiple Sclerosis Patients and Healthy Controls: Implications for Clinical Trials.","authors":"Pavan Bhargava, Andrew Lang, Omar Al-Louzi, Aaron Carass, Jerry Prince, Peter A Calabresi, Shiv Saidha","doi":"10.1155/2015/136295","DOIUrl":"10.1155/2015/136295","url":null,"abstract":"<p><p>Background. The lack of segmentation algorithms operative across optical coherence tomography (OCT) platforms hinders utility of retinal layer measures in MS trials. Objective. To determine cross-sectional and longitudinal agreement of retinal layer thicknesses derived from an open-source, fully-automated, segmentation algorithm, applied to two spectral-domain OCT devices. Methods. Cirrus HD-OCT and Spectralis OCT macular scans from 68 MS patients and 22 healthy controls were segmented. A longitudinal cohort comprising 51 subjects (mean follow-up: 1.4 ± 0.9 years) was also examined. Bland-Altman analyses and interscanner agreement indices were utilized to assess agreement between scanners. Results. Low mean differences (-2.16 to 0.26 μm) and narrow limits of agreement (LOA) were noted for ganglion cell and inner and outer nuclear layer thicknesses cross-sectionally. Longitudinally we found low mean differences (-0.195 to 0.21 μm) for changes in all layers, with wider LOA. Comparisons of rate of change in layer thicknesses over time revealed consistent results between the platforms. Conclusions. Retinal thickness measures for the majority of the retinal layers agree well cross-sectionally and longitudinally between the two scanners at the cohort level, with greater variability at the individual level. This open-source segmentation algorithm enables combining data from different OCT platforms, broadening utilization of OCT as an outcome measure in MS trials. </p>","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2015 ","pages":"136295"},"PeriodicalIF":2.2,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452193/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33402957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Multiple Sclerosis International
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1